LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Search

Teva Pharmaceutical Industries Ltd.

Closed

SectorHealthcare

33.95 -1.05

Overview

Share price change

24h

Current

Min

33.7

Max

34.29

Key metrics

By Trading Economics

Income

47M

481M

Sales

231M

4.7B

P/E

Sector Avg

28.488

121.746

EPS

0.96

Profit margin

10.21

Employees

31,173

EBITDA

-474M

632M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+14.97% upside

Market Stats

By TradingEconomics

Market Cap

2.8B

40B

Previous open

35

Previous close

33.95

News Sentiment

By Acuity

57%

43%

293 / 352 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Teva Pharmaceutical Industries Ltd. Chart

Past performance is not a reliable indicator of future results.

Related News

9 Oct 2025, 09:10 UTC

Hot Stocks

Stocks to Watch Thursday: HSBC, PepsiCo, MP Materials -- WSJ

7 May 2025, 17:01 UTC

Top News

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

Peer Comparison

Price change

Teva Pharmaceutical Industries Ltd. Forecast

Price Target

By TipRanks

14.97% upside

12 Months Forecast

Average 39.63 USD  14.97%

High 45 USD

Low 37 USD

Based on 11 Wall Street analysts offering 12 month price targets forTeva Pharmaceutical Industries Ltd. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

10

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

15.58 / N/ASupport & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

293 / 352 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
help-icon Live chat